Fresh analysis reveals that patients who discontinue new GLP-1 drugs like Wegovy and Mounjaro may regain lost weight at a significantly accelerated pace than those who stop conventional lifestyle regimens.
Published data in a major health publication shows that while obese people often shed substantial amounts of their total mass while using the jabs, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals buying such drugs should be cognizant of the danger of rapid rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
This pace of regain implies a reversion to starting weight in about 18 months.
Analyzing Approaches
The analysis, which examined dozens of studies involving thousands of patients, compared the results of the injectable medications with older methods.
Researchers emphasize that individuals who lose weight through lifestyle changes alone usually have a less rapid weight regain—approximately 0.1 kg a month—post-intervention.
Understanding the Rapid Rebound
Experts believe the mechanism of the injections is key to understanding the accelerated weight return.
The injections imitate a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Artificially providing GLP-1 concentrations several times higher than normal may cause the body to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this medication leads to hunger is uncontrolled, making binge eating far more likely."
A Lifelong Disease?
Health authorities recommend the injections for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts argue that, considering the significant potential of relapse, the treatment should be considered long-term.
This view is supported by pharmaceutical companies, who note that the findings "emphasize the chronic nature of excess weight," similar to managing conditions like diabetes.
User Accounts
People who have stopped the medication report a powerful return of appetite.
"It was like a switch flipping and I was suddenly ravenous," said one woman.
This challenge is worsened if patients have not established lasting dietary or behavioural modifications during treatment.
Significant Use
Figures suggest that millions of adults in the UK have tried these injections in the last 12 months, with demand being substantial.
- Adoption is greater among females compared to males.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone solution and lasting health benefits likely depends on combined behavioural changes.
